Wednesday broker round-up UPDATE
27th Feb 2013 08:11
: Panmure Gordon reduces target price from 2159p to 1742p and reiterates its hold recommendation. Antofagasta: JP Morgan cuts target price from 1485p to 1400p, while retaining its overweight rating. Barclays: Numis raises target price from 351p to 400p and upgrades to buy. BT Group: UBS moves tar
Read moreDechra Pharmaceuticals records rise in revenues and profits
26th Feb 2013 07:37
Dechra Pharmaceuticals raised its dividend by 15.1 per cent as the company achieved higher revenues and profits during the second half of 2012. The veterinary medicines company returned an interim dividend per share of 4.34p, compared to 3.77p for the same period a year earlier. Group revenues cl
Read moreTuesday broker round-up UPDATE
26th Feb 2013 07:27
Andor Technology: Investec shifts target price from 460p to 500p and keeps a buy recommendation. Associated British Foods: Nomura revises target price from 1790p to 1800p, while its neutral rating remains unchanged. Barclays: Espirito Santo raises target price from 346p to 418p and reiterates its
Read moreDechra appoints new Chief Financial Officer
31st Jan 2013 08:05
Veterinary pharmaceutical company Dechra announced Thursday the appointment of Anne-Francoise Nesmes as Chief Financial Officer. Nesmes joins the company on April 22nd from GlaxoSmithKline where she has worked since 1997 in a number of finance roles including Senior Vice-President, Finance of Vacci
Read moreWednesday tips round-up: Rexam, Dechra Pharmaceuticals, Cineworld
9th Jan 2013 06:44
Selling on about 11 times 2013 holdings consumer packaging giant Rexam looks a solid long-term investment, given the prospects of further cash returns, the Times's Tempus column wrote last night. That follows the company's announcement on Wednesday that the company is set to return 395m pounds to it
Read moreDechra sees slowdown of growth in European sector
8th Jan 2013 08:57
Dechra Pharmaceuticals said in a trading statement Tuesday that its first half has been in line with management expectations, but admitted its European Pharmaceuticals segment saw growth slow from 73.7 per cent to 61.4 per cent year-on-year. The reported divisional performance over the correspondi
Read moreTuesday broker round-up UPDATE
8th Jan 2013 07:19
Anglo American: Deutsche Bank reduces target price from 2270p to 2230p and maintains its buy recommendation. Aquarius Platinum: Deutsche Bank ups target price from 73p to 76p, while the buy rating remains unchanged. ARM Holdings: Credit Suisse raises target price from 645p to 780p and reiterates a
Read moreLondon pre-open: FTSE set to edge lower
22nd Oct 2012 07:22
City sources predict the FTSE 100 will open down nine points from Friday's close of 5,896 as attention remains focused on the Eurozone. It has been reported that Greece is close to securing the release of the next bailout package, worth €31.5bn. Speaking in Bucharest at the end of last week, Gree
Read moreSunday share tips: Aggreko, Dechra, Optos
21st Oct 2012 10:42
Friday's trading statement from temporary power group Aggreko indicated a robust third quarter, with revenues up 22%. However, the shares tumbled by 7% as a number of headwinds emerged. Similarly, Rupert Soames, Aggreko's chief executive, was cautious about economic prospects for next year. He is ri
Read moreDechra's Finance Director gallops away
19th Oct 2012 07:47
Dechra Pharmaceutical's Group Finance Director, Simon Evans, has quit suddenly after 15 years in the job, and won't be sticking around to work with his successor. In a brief statement the veterinary pharmaceuticals company said: "Simon recognises that following the acquisitions of Eurovet and Vetxx
Read moreWednesday tips round-up: Genus, Ashtead, Dechra
5th Sep 2012 07:20
In The Times, the Tempus column kicks off with animal semen producer Genus, which dropped yesterday as investors worried about the price of feedstocks like corn in the agricultural sector. But Genus has been a major success story, providing the gene pool to increase yields for pig and cow farmers ac
Read moreFTSE 250 movers: Ashtead jumps after bullish guidance
4th Sep 2012 14:43
While the miners were dominating the downward trend on the second-tier FTSE 250 index on Tuesday afternoon, there were a handful of outperformers, most notably high-flying plant hire firm Ashtead. Ashtead saw shares jump after saying this morning that full-year results will be "materially ahead of
Read moreLondon midday: Evraz leads fallers on the FTSE 100
4th Sep 2012 11:53
- Investors in 'wait and see mode' ahead of ECB - Markets await pivotal US ISM data - Moody's lower EU outlook to 'negative' The FTSE 100 had slumped to its lowest levels of the day by Tuesday lunchtime as investors were cautious about building positions ahead of some pivotal US economic data this
Read moreTuesday broker round-up
4th Sep 2012 09:31
Ashtead: Jefferies lifts target from 360p to 320p, buy rating kept. Barclays: JP Morgan downgrades to neutral from overweight, target cut from 265p to 250p. British Land: UBS downgrades to neutral, target cut from 575p to 560p. Capital Shopping Centres Group: UBS upgrades to buy, target lifted fr
Read moreLondon open: Stocks slip before US data
4th Sep 2012 08:30
- Moody's lower EU rating to 'negative' - Markets await US ISM data - Investors keep eyes pinned on ECB UK stocks pulled back on Tuesday morning following a strong performance the day before as some gloomy comments from Moody's and caution ahead of some US economic data dampened sentiment. Yesterd
Read more